Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance.
Segolene HescotJulien Masliah-PlanchonPauline du RusquecCélia DupainMaud KamalVincent ServoisIvan BiechePublished in: European thyroid journal (2022)